Skip to main content

Table 2 Ongoing studies of first-line treatments for HER2 positive metastatic breast cancer

From: First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Study Arms of Treatment Population N. of patients Obiectives of Study
Peruse (MO28047) P + T + Tx mBC HER 2+ 1436 Multicenter clinical practice, single-arm phase IV study to evaluate the safety of the combination in real life world
Pertain (MO27775) P + T + AI vs T + AI mBC HER2+ HR+ Post menopausal status 250 Randomized multicenter open label phase II study designed to assess the efficacy and safety of P+ T + AI [anastrozole or letrozole) or T+ AI. Pts in either arm may also receive induction chemotherapy for up to 18 weeks at the investigator’s discretion.
Velvet (MO27782) P + T + VNR mBC HER2+ 210 Randomized, multicenter open-label, single-arm with 2 cohorts of patients (cohort 1 = sequential infusion of P and T; cohort 2 concomitant P and T) designed to evaluate the efficacy and safety of P in combination with VNR
Metapher (BO29159) P + T (s.c) + Tx mBC HER2+ 400 Multicenter single-arm phase IIIb study, designed to evaluate the safety and efficacy of the combination P + T subcutaneously + Tx
  1. P Pertuzumab, T Trastuzumab, Tx Docetaxel or Paclitaxel or nabPaclitaxel, VNR Vinorelbine, AI aromatase inhibitor, mBC metastatic Breast Cancer, s.c. subcutaneous